Compare SLE & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLE | EVAX |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 31.9M |
| IPO Year | 2019 | 2020 |
| Metric | SLE | EVAX |
|---|---|---|
| Price | $4.00 | $4.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $60.00 | $11.67 |
| AVG Volume (30 Days) | 23.1K | ★ 31.6K |
| Earning Date | 05-14-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,064,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $26.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 90.41 | N/A |
| 52 Week Low | $0.10 | $1.20 |
| 52 Week High | $11.43 | $12.15 |
| Indicator | SLE | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 45.05 | 48.56 |
| Support Level | $3.16 | $2.45 |
| Resistance Level | $5.24 | $4.64 |
| Average True Range (ATR) | 0.53 | 0.40 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 1.78 | 34.71 |
Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.